FDA Approves Darolutamide Tablets for Metastatic Hormone-Sensitive Prostate Cancer
Evidence for efficacy is based on the results from the ARASENS study
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1533 results
Marginal Benefit in Overall and Progression-Free Survival from New Anticancer Drugs
New anticancer drugs substantially reduce the risk of death and tumour progression, but only marginally extend patient survival
EMA Recommends Granting a Marketing Authorisation for Nivolumab / Relatlimab
It is indicated for the first-line treatment of advanced melanoma in adults and adolescents 12 years of age and older with tumour cell PD-L1 expression < 1%
Neoadjuvant Niraparib Demonstrates Promising Antitumour Activity and Safety in Patients with Localised HER2-negative, BRCA-mutated Breast Cancer
Findings from the single-arm, phase II study
Trastuzumab Deruxtecan Shows High Intracranial Response Rate in Patients with Active Brain Metastases from HER2-positive Breast Cancer
Findings from the TUXEDO-1 study
Molecular Profiling Identifies Targetable Alterations in Majority of Patients with Advanced Rare Gastrointestinal Malignancies
Findings from the ARCAGEN study (EORTC-1843)
Largest Study on Frequent Aspirin Use Supports Reduction in Ovarian Cancer Risk
Findings from an analysis of data from two ovarian cancer consortia
Genetic Risk Score Increases Prediction of Severe Obesity in Adult Survivors of Childhood Cancer
Genetic testing, along with assessment of clinical risk factors, could be used to identify survivors at high risk for severe obesity and associated cardio-metabolic complications
EMA Recommends Granting a Marketing Authorisation for Lutetium (177lu) Chloride
This radiopharmaceutical precursor must be used only for the radiolabelling of carrier medicines that have been specifically developed and authorised for radiolabelling with lutetium chloride
KRASG12D-Mutated NSCLC is Subtype with Distinct Co-mutations, a Colder Immune Microenvironment, and Worse Outcomes to PD-1 Blockade Monotherapy
Findings from a comprehensive analysis of the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small cell lung cancer
Antitumour Activity of Combination of Lenvatinib and Pembrolizumab in Patients with Advanced Melanoma with Confirmed Progression on Previous Anti-PD-(L)1-Based Treatment
Findings from the LEAP-004 study
Significant 20-Year Benefit of 2 Years of Adjuvant Goserelin and Tamoxifen in ER-Positive Premenopausal Patients with Breast Cancer
Findings from the STO-5 study